Mustang Bio Inc(MBIO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.45 | Insider Own | 14.98% | Shs Outstand | 6.7M | Perf Week | 8.14% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 6.4M | Perf Month | -14.36% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | - | Inst Own | 7.11% | Short Float | 0.91% | Perf Quarter | -30.61% |
| Income | -0.00B | P/S | - | EPS this Y | - | Inst Trans | 0.41% | Short Ratio | 1.91 | Perf Half Y | -46.96% |
| Sales | 0.00B | P/B | 0.4 | EPS next 5Y | - | ROA | -21.17% | Short Interest | 0.06M | Perf YTD | -59.22% |
| Book/sh | 1 | P/C | 0.2 | EPS past 3/5Y | 91.14% 78.52% | ROE | -58.12% | 52W High | -73.08% ($1.49) | Perf Year | -72.6% |
| Cash/sh | 2 | P/FCF | - | Sales past 3/5Y | - | ROIC | -40.2% | 52W Low | 14.22% ($0.35) | Perf 3Y | -99.45% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 85.52% | Gross Margin | - | Volatility(W/M) | 8.46% 7.88% | Perf 5Y | -99.98% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.03 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.97 | EPS Q/Q | 15.99% | Profit Margin | - | RSI (14) | 44.72 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.97 | Sales Q/Q | - | SMA20 | 1.86% ($0.39) | Beta | 2.2 | Target Price | $500 |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | -15.18% ($0.47) | Rel Volume | 1.57 | Prev Close | $0.39 |
| Employees | 4 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -150% - | SMA200 | -41.76% ($0.69) | Avg Volume(3M) | 0.03M | Price | $0.4 |
| IPO | 2017/8/22 | Option/Short | No/Yes | Trades | 182 | Volume | 48,296 | Change | 1.94% |
🧬 Mustang Bio () is a US clinical-stage biotech developing CAR-T (chimeric antigen receptor T-cell)-based cell and gene therapies. Its core assets include MB-101, an IL13Rα2-targeting CAR-T for glioblastoma, the MB-109 combination pairing MB-101 with the oncolytic virus MB-108, and MB-106 for non-Hodgkin lymphoma. MB-101 has received FDA Orphan Drug Designation.
Over the past 1 year, on the lower side
73% below its 1-year high.
Traded more than usual. That is 157% of its average volume.
MBIO has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 7.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #565 of 597 in the industry
Based on market cap of $3M.
EOCN#561 Eocene Ltd $3M PER - 
ERNA#562 Ernexa Therapeutics Inc $3M PER - 
KALA#563 Kala Bio Inc $3M PER - 
CMND#564 Clearmind Medicine Inc $3M PER - MBIO#565 Mustang Bio Inc $3M PER - 
FAQ
What kind of company is MBIO?
MBIO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MBIO?
The market cap of MBIO is approximately $3M, ranking 5,730 within its sector.
What is the 52-week high and low for MBIO?
MBIO has recorded a 52-week high of $1.49 and a low of $0.35.
